simCYD14_twostage: Simulated CYD14 Two-Phase Data Set
In brendalewisprice/IPCWTMLE2Phase: Inverse Probability of Censoring Weighted Targeted Minimum Loss-based Estimation for Two-Phase STudies

Data simulated to mimic the CYD14 Tetravalent Dengue Vaccine Trial conducted by Sanofi-Pasteur

1	data(simCYD14_twostage)

A data frame simulated to mimic a phase 3 dengue vaccine efficacy trial with 10250 rows and the following 40 variables:

X: Row number
STUDYID: Study name
SUBJID: Subject ID
VACC: Vaccination status: vaccine=1; placebo=0
AGEYRS: Subject age at enrollment
SEX: M=male; F=female
Male: Binary indicator: 1=male, 0=female
COUNTRY: Country code
IDN-MEX: Country code indicator variables
VCD: Any VCD (virally confirmed dengue)=1, no VCD=0
VCD_Sero1-VCD_Sero4: Indicator of VCD specific serotype 1 - serotype 4
baseline_PRNT_Sero1-baseline_PRNT_Sero4: Baseline serotype PRNT titers for serotypes 1-4
baseline_PRNT_SeroAverage: Geometric mean of baseline PRNT titers
M13_PRNT_Sero1-M13_PRNT_Sero4: M13 serotype PRNT titers for serotypes 1-4
M13_PRNT_SeroAverage: Geometric mean of M13 PRNT titers
M13_MNv2_Sero1-M13_MNv2_Sero4: M13 serotype MNv2 titers for serotypes 1-4
M13_MNv2_SeroAverage: Geometric mean of M13 MNv2 titers
weight: Observation level sampling weight for sampling to phase-two
delta: Indicator of sampling to phase-two sample

Capeding et al. (2014) The Lancet 384:1358–1365

brendalewisprice/IPCWTMLE2Phase documentation built on Nov. 4, 2019, 8:12 a.m.

brendalewisprice/IPCWTMLE2Phase index

Note that we can't provide technical support on individual packages. You should contact the package authors for that.

Description